Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large cap stocks Jim Cramer can’t stop talking about. In a recent episode of Mad ...

A pair of late-stage trials found that Eli Lilly & Co.’s experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...

Sept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), opens new tab, filed for an initial public offering in the United States on ...

The primary cause for the selloff could be because Eli Lilly (NYSE:LLY) has cut the knees out from under Hims & Hers biggest selling point: selling weight-loss drugs at a steep discount.

Indianapolis-based Eli Lilly and Co. is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed ...

Eli Lilly is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed cheaper, off-brand ...

Hutchmed co-markets the drug with Eli Lilly in China under the brand name Elunate, while Takeda holds ex-China rights. Hutchmed made the decision after realizing that an approval is unlikely at ...